MCRB Seres Therapeutics Inc
Price (delayed)
$0.678
Market cap
$118.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$170.39M
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to
Highlights
Seres Therapeutics's net income has soared by 101% from the previous quarter and by 100% YoY
The EPS has soared by 100% QoQ and by 100% YoY
The equity has soared by 131% YoY but it has decreased by 42% QoQ
The quick ratio fell by 27% YoY and by 14% QoQ
Key stats
What are the main financial stats of MCRB
Market
Valuations
Earnings
Shares outstanding
174.36M
Market cap
$118.22M
Enterprise value
$170.39M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.4
Price to sales (P/S)
N/A
EV/EBIT
1,252.9
EV/EBITDA
11.49
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$121.32M
Net income
$136,000
EBIT
$136,000
EBITDA
$14.83M
Free cash flow
-$148.99M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.96
Book value per share
$0.08
Revenue per share
$0
TBVPS
$0.9
Total assets
$139.81M
Total liabilities
$126.03M
Debt
$91.64M
Equity
$13.78M
Working capital
-$2.55M
Debt to equity
6.65
Current ratio
0.94
Quick ratio
1.01
Net debt/EBITDA
3.52
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
0.1%
Return on equity
N/A
Return on invested capital
0.1%
Return on capital employed
0.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MCRB stock price
How has the Seres Therapeutics stock price performed over time
Intraday
0.27%
1 week
-7.12%
1 month
-10.71%
1 year
-11.12%
YTD
-18.41%
QTD
-3.16%
Financial performance
How have Seres Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$121.32M
Net income
$136,000
Gross margin
N/A
Net margin
N/A
Seres Therapeutics's net income has soared by 101% from the previous quarter and by 100% YoY
MCRB's operating income is up by 38% year-on-year and by 12% since the previous quarter
Growth
What is Seres Therapeutics's growth rate over time
Valuation
What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
8.4
P/S
N/A
EV/EBIT
1,252.9
EV/EBITDA
11.49
EV/Sales
N/A
The EPS has soared by 100% QoQ and by 100% YoY
The equity has soared by 131% YoY but it has decreased by 42% QoQ
Efficiency
How efficient is Seres Therapeutics business performance
The return on invested capital has surged by 102% since the previous quarter and by 100% year-on-year
The company's return on assets has surged by 101% QoQ and by 100% YoY
Dividends
What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MCRB.
Financial health
How did Seres Therapeutics financials performed over time
The total assets is 11% higher than the total liabilities
The total liabilities has plunged by 69% YoY and by 19% from the previous quarter
The total assets has shrunk by 61% YoY and by 22% QoQ
The equity has soared by 131% YoY but it has decreased by 42% QoQ
Seres Therapeutics's debt to equity has surged by 70% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.